help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2004-0182
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ezzat, S.
Right arrow Articles by Asa, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ezzat, S.
Right arrow Articles by Asa, S. L.
Molecular Endocrinology 18 (10): 2543-2552
Copyright © 2004 by The Endocrine Society

Pituitary Tumor-Derived Fibroblast Growth Factor Receptor 4 Isoform Disrupts Neural Cell-Adhesion Molecule/N-Cadherin Signaling to Diminish Cell Adhesiveness: A Mechanism Underlying Pituitary Neoplasia

Shereen Ezzat, Lei Zheng and Sylvia L. Asa

Departments of Medicine (S.E., L.Z.), Laboratory Medicine and Pathobiology (S.L.A.), University of Toronto; The Freeman Centre for Endocrine Oncology (S.E., L.Z., S.L.A.), Mount Sinai Hospital; and Ontario Cancer Institute (S.E., L.Z., S.L.A.), University Health Network, Toronto, Ontario, Canada M5G-1X5

Address all correspondence and requests for reprints to: Dr. S. Asa, 610 University Avenue, 4-302, Toronto, Ontario, Canada M5G-2M9. E-mail: sylvia.asa{at}uhn.on.ca.

We previously identified pituitary tumor-derived fibroblast growth factor receptor 4 (ptd-FGFR4), an alternatively transcribed N-terminally truncated cytoplasmic receptor isoform. Unlike wild-type FGFR4, ptd-FGFR4 facilitates cell transformation and results in pituitary tumor formation in transgenic mice. To investigate differences in the tumorigenic properties of FGFR4 and ptd-FGFR4, we examined their abilities to modulate cell adhesiveness. Introduction of ptd-FGFR4 into GH4 pituitary cells or NIH 3T3 fibroblasts resulted in significant reduction in cell adhesion to a collagen IV matrix compared with FGFR4- or empty vector-transfected cells. This adhesive difference was evident in the absence or presence of FGF stimulation. Furthermore, treatment with ß1-integrin neutralizing antibody markedly reduced adhesiveness in FGFR4-transfected cells but had little effect on the depressed adhesiveness of ptd-FGFR4-transfected cells. Unlike wild-type FGFR4, ptd-FGFR4 does not associate with neural cell-adhesion molecule (NCAM). Cells expressing FGFR4 demonstrate membranous N-cadherin with a noninvasive growth pattern identical to control GH4 cells when injected into immunodeficient mice. In contrast, ptd-FGFR4-expressing cells develop invasive tumors in vivo with marked loss of N-cadherin that localizes to the cytoplasm. Consistent with these changes, ß-catenin expression was diminished and its interaction with N-cadherin was disrupted in the presence of ptd-FGFR4, but both were intact in the presence of wild-type FGFR4. These data highlight the importance of membrane-anchored FGFR4 in assembling a multiprotein FGFR4 complex with NCAM and N-cadherin playing pivotal functions in maintaining normal cell adhesion. Disruption of distinct NCAM/N-cadherin proadhesive complexes by a tumor-derived FGFR4 isoform provides a novel mechanism beyond ligand independence that explains the pathobiology of proliferative and infiltrative but nonmetastatic neoplasms.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
P. Poomthavorn, S. H X Wong, S. Higgins, G. A Werther, and V. C Russo
Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells
Endocr. Relat. Cancer, September 1, 2009; 16(3): 991 - 1004.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Xu, L. Shorts-Cary, A. J. Knox, B Kleinsmidt-DeMasters, K. Lillehei, and M. E. Wierman
Epidermal Growth Factor Receptor Pathway Substrate 8 Is Overexpressed in Human Pituitary Tumors: Role in Proliferation and Survival
Endocrinology, May 1, 2009; 150(5): 2064 - 2071.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X. Zhu, S. L. Asa, and S. Ezzat
Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia
Clin. Cancer Res., April 1, 2008; 14(7): 1984 - 1996.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Cristina, G. Diaz-Torga, A. Gongora, M. C. Guida, M. I. Perez-Millan, A. Baldi, and D. Becu-Villalobos
Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1341 - E1351.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
X. Zhu, K. Lee, S. L. Asa, and S. Ezzat
Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells
Am. J. Pathol., May 1, 2007; 170(5): 1618 - 1628.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
S. A. Boikos and C. A. Stratakis
Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis
Hum. Mol. Genet., April 15, 2007; 16(R1): R80 - R87.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. Shorts-Cary, M. Xu, J. Ertel, B. K. Kleinschmidt-Demasters, K. Lillehei, I. Matsuoka, S. Nielsen-Preiss, and M. E. Wierman
Bone Morphogenetic Protein and Retinoic Acid-Inducible Neural Specific Protein-3 Is Expressed in Gonadotrope Cell Pituitary Adenomas and Induces Proliferation, Migration, and Invasion
Endocrinology, March 1, 2007; 148(3): 967 - 975.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Ezzat, L. Zheng, D. Winer, and S. L. Asa
Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications
Mol. Endocrinol., November 1, 2006; 20(11): 2965 - 2975.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Ezzat, X. Zhu, S. Loeper, S. Fischer, and S. L. Asa
Tumor-Derived Ikaros 6 Acetylates the Bcl-XL Promoter to Up-Regulate a Survival Signal in Pituitary Cells
Mol. Endocrinol., November 1, 2006; 20(11): 2976 - 2986.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao
Advances in the Treatment of Prolactinomas
Endocr. Rev., August 1, 2006; 27(5): 485 - 534.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S Ezzat and S L Asa
The molecular pathogenetic role of cell adhesion in endocrine neoplasia
J. Clin. Pathol., November 1, 2005; 58(11): 1121 - 1125.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Ezzat, S. Yu, and S. L. Asa
The Zinc Finger Ikaros Transcription Factor Regulates Pituitary Growth Hormone and Prolactin Gene Expression through Distinct Effects on Chromatin Accessibility
Mol. Endocrinol., April 1, 2005; 19(4): 1004 - 1011.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ezzat, P. Huang, A. Dackiw, and S. L. Asa
Dual Inhibition of RET and FGFR4 Restrains Medullary Thyroid Cancer Cell Growth
Clin. Cancer Res., February 1, 2005; 11(3): 1336 - 1341.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society